Surgery Partners, Inc.
NASDAQ:SGRYMedical - Care Facilities
+$0.06 today
- Market cap
- $3.53B
- Beta
- 1.95
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.59
Volume 3.24M
Average 1.36M
SGRY Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Surgery Partners, Inc.NASDAQ: SGRY
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income dips below year-ago levels
Q3 FY2026 net income of $14.1M fell 44.3% year over year, behind the +230.0% change in trailing-twelve-month net income. Sequentially, it fell 60.7% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.
Context
- Net income amounted to 3.0% of revenue in FY2025, up 2.6 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $48M (-51.5%) for the fiscal year ending Dec 2026, a slowdown from the +691.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $14.1M-60.7% QoQ
- Last fiscal yearDec 2025
- $98.9M+691.2% YoY
- LTMSep 2026
- $76.9M+230.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.3% | +24.6% | +68.8 pp |
| 1 year | +691.2% | -51.5% | -742.7 pp |
| 3-year CAGR | +4.4% | -11.9% | -16.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 98.9M USD
- Year-over-year change
- +691.2%
- 4-year CAGR
- +8.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.9M | +691.2% |
| FY2024 | 2024-12-31 | 12.5M | -90.8% |
| FY2023 | 2023-12-31 | 135.3M | +55.5% |
| FY2022 | 2022-12-31 | 87M | +23.1% |
| FY2021 | 2021-12-31 | 70.7M | — |
Net Income vs competitors
How SGRY compares with its peers on the latest reported figures
- SGRY's LTM Sep 2026 net income of $76.9M is the smallest of the 7 companies compared; the peer median is $1.01B.
- Its year-over-year change of +230.0% is the highest of 7, against a peer median of +15.7%.
- Net income amounts to 2.3% of revenue for SGRY, versus a peer median of 8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.84B | +3.1% | -0.2% | 8.8% | |
| LTM Jun 2026 | $2.68B | +11.9% | +12.0% | 12.3% | |
| LTM Jun 2026 | $1.53B | +19.5% | +32.0% | 8.4% | |
| LTM Mar 2026 | $497M | +202.1% | +144.9% | 2.3% | |
| LTM Mar 2026 | $187.54M | +33.9% | — | 21.3% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $186.34M | -23.1% | -4.6% | 2.9% |
| LTM Sep 2026 | $76.9M | +230.0% | +4.4% | 2.3% | |
| Peer median (excluding SGRY) | $1.01B | +15.7% | +12.0% | 8.6% | |
Competitors are the stored peer set for SGRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 70.7M | 87M | 135.3M | 12.5M | 98.9M |
| Depreciation & Amortization | 98.8M | 114.8M | 118.1M | 152.6M | 176M |
| Deferred Income Tax | 8.9M | 21.9M | (1.7M) | 131.5M | 16.7M |
| Stock-Based Compensation | 17.4M | 18.4M | 17.7M | 33.3M | 14.8M |
| Change in Working Capital | (149.1M) | (102.3M) | (62.3M) | (118.9M) | (110.4M) |
| Accounts Receivables | (32.1M) | (35.3M) | (47.2M) | (72.1M) | (53.8M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (117M) | (67M) | (15.1M) | (46.8M) | (56.6M) |
| Other Non-Cash Items | 40.4M | 19M | 86.7M | 89.1M | 78.3M |
| Operating Cash Flow | 87.1M | 158.8M | 293.8M | 300.1M | 274.3M |
| Capital Expenditures | (57.6M) | (80.6M) | (88.8M) | (90.4M) | (78.7M) |
| Acquisitions (Net) | (280.4M) | (228.7M) | (128.9M) | (378.8M) | (162.1M) |
| Purchases of Investments | 0 | 0 | 0 | (1.7M) | (13.3M) |
| Sales of Investments | 0 | 0 | 0 | 4.6M | 0 |
| Other Investing Activities | 6.3M | 1.4M | (7.9M) | (22.2M) | 7.5M |
| Investing Cash Flow | (331.7M) | (307.9M) | (225.6M) | (488.5M) | (246.6M) |
| Debt Repayment | (43.8M) | (644.2M) | 19.5M | 450.4M | 158.7M |
| Common Stock Issued | 581.8M | 882.9M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (5.1M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (216.6M) | (196.6M) | (174.7M) | (188.4M) | (216M) |
| Financing Cash Flow | 316.3M | 42.1M | (155.2M) | 262M | (57.3M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.7M | (107M) | (87M) | 73.6M | (29.6M) |
| Free Cash Flow | 29.5M | 78.2M | 205M | 209.7M | 195.6M |
Surgery Partners, Inc.
NASDAQ:SGRY
Intrinsic Alpha fair value
Locked
Current Price
$26.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.